Mon, Dec 22, 2014, 5:44 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Guided Therapeutics, Inc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • sexyladyfitness sexyladyfitness Dec 8, 2009 2:29 PM Flag

    Whats going on with this Company?

    Colposcopy I meant-
    I think Company is shying away from main use with Pap Smear and more with Colposcopy ,which is used when pap smear shows a problem..This decreases market value..
    The FDA process is slow in evaluating devices but that has nothing to do with the the Company NOT submitting the full PMA application.What is Guided Therapeutics excuse for this prolonged delay?
    -The Light Touch pre-clinical module was submitted 2 years ago! FDA awaits the Clinical and Manufacturing module of the Device and until then Light Touch will not be approved.
    FDA has NOT received module 2 and module 3 >though Company has made promises for almost 2 years now....,
    thats my Concern.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I don't think the company can submit manufacturing and clinical modules until they have a detailed plan, which in this case requires the agreement of manufacturing partner(s). Also, the company states that it is working with third party insurers who will provide reimbursement, etc. to patients. Without this financial "structure" the Light-Touch would, if introduced prematurely, exist in a marketing vacuum. Perhaps the delay involves the detailed structuring of the business end with partners.

      As far as colopscopy is concerned, it will be used in the case of an abnormal reading with Lite-Touch, just as it is used with an abnormal pap smear. The Light-Touch is a screening tool. All screening tools require a biopsy when an abnormal reading comes up.

0.298+0.001(+0.34%)Oct 30 2:14 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.